TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Kuwahara, Akiko ^a,c   Yamamori, Motohiro ^a,b,c   Fujita, Megumi ^a,c   Okuno, Tatsuya ^c   Tamura, Takao ^c   Kadoyama, Kaori ^b,c   Okamura, Noboru ^a,c   Nakamura, Tsutomu ^c   Sakaeda, Toshiyuki ^b,c  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DNA POLYMORPHISM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE; GENOTYPE; HUMAN; JAPANESE; LYMPH NODE METASTASIS; MALE; METASTASIS; PRIORITY JOURNAL; RADIATION DOSE; TNFRSF1A GENE; TUMOR VOLUME; ESOPHAGUS TUMOR; GENETIC POLYMORPHISM; GENETICS; JAPAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENOTYPE; HUMANS; JAPAN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RADIOTHERAPY DOSAGE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954681460     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-100     Document Type: Article

References (30)

1. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JS Cooper MD Guo A Herskovic JS Macdonald JA Martenson Jr M Al-Sarraf R Byhardt AH Russell JJ Beitler S Spencer SO Asbell MV Graham LL Leichman, JAMA 1999 281 1623 1627 10.1001/jama.281.17.1623 10235156
2. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. A Ohtsu N Boku K Muro K Chin M Muto S Yoshida M Satake S Ishikura T Ogino Y Miyata S Seki K Kaneko A Nakamura, J Clin Oncol 1999 17 2915 2921 10561371
3. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. K Kaneko H Ito K Konishi T Kurahashi T Ito A Katagiri T Yamamoto T Kitahara Y Mizutani A Ohtsu K Mitamura, Br J Cancer 2003 88 18 24 10.1038/sj.bjc.6600684 12556953
4. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. M Tahara A Ohtsu S Hironaka N Boku S Ishikura Y Miyata T Ogino S Yoshida, Jpn J Clin Oncol 2005 35 316 323 10.1093/jjco/hyi095 15961436
5. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. S Ishikura K Nihei A Ohtsu N Boku S Hironaka K Mera M Muto T Ogino S Yoshida, J Clin Oncol 2003 21 2697 2702 10.1200/JCO.2003.03.055 12860946 (Pubitemid 46606313)
6. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. T Sakaeda M Yamamori A Kuwahara K Nishiguchi, Adv Drug Deliv Rev 2009 61 388 401 10.1016/j.addr.2008.10.005 19135108
7. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. I Miki T Tamura T Nakamura H Makimoto N Hamana H Uchiyama D Shirasaka Y Morita H Yamada N Aoyama T Sakaeda K Okumura M Kasuga, Ther Drug Monit 2005 27 369 374 10.1097/01.ftd.0000162554.23501.e6 15905809
8. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for Stage II/III esophageal squamous cell carcinoma in Japanese. T Okuno T Tamura M Yamamori N Chayahara T Yamada I Miki N Okamura Y Kadowaki D Shirasaka N Aoyama T Nakamura K Okumura T Azuma M Kasuga T Sakaeda, Am J Clin Oncol 2007 30 252 257 10.1097/01.coc.0000256059.88247.25 17551301
9. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. T Sakaeda M Yamamori A Kuwahara S Hiroe T Nakamura K Okumura T Okuno I Miki N Chayahara N Okamura T Tamura, Ther Drug Monit 2008 30 497 503 18641541
10. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. S Cucchiara A Latiano O Palmieri RB Canani R D'Inc G Guariso G Vieni D De Venuto G Riegler GL De'Angelis D Guagnozzi C Bascietto E Miele MR Valvano F Bossa V Annese Italian Society of Pediatric Gastroenterology and Nutrition, J Pediatr Gastroenterol Nutr 2007 44 171 179 10.1097/MPG.0b013e31802c41f3 17255827
11. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. H Sashio K Tamura R Ito Y Yamamoto H Bamba T Kosaka S Fukui K Sawada Y Fukuda K Tamura M Satomi T Shimoyama J Furuyama, Immunogenetics 2002 53 1020 1027 10.1007/s00251-001-0423-7 11904678
12. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G>A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease. J Skora I Subrt P Ddek K Siala J Schwarz V Machalov J Varvarovsk P Pazdiora O Pozler F Stozick J Pediatr Gastroenterol Nutr 2006 42 479 487 10.1097/01.mpg.0000221917.80887.9e 16707968
13. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. KA Waschke AC Villani S Vermeire L Dufresne TC Chen A Bitton A Cohen AB Thomson GE Wild, Am J Gastroenterol 2005 100 1126 1133 10.1111/j.1572-0241.2005.40534.x 15842589
14. Effect of the polymorphism of tumor necrosis factor-alpha-308 G/A gene promoter on the susceptibility to ulcerative colitis: a meta-analysis. Z Lu L Chen H Li Y Zhao L Lin, Digestion 2008 78 44 51 10.1159/000158605 18827481
15. Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population. C Kiyohara M Washio T Horiuchi Y Tada T Asami S Ide T Atsumi G Kobashi H Takahashi Kyushu Sapporo SLE (KYSS) Study Group, J Rheumatol 2009 36 2195 2203 10.3899/jrheum.090181 19684152
16. A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis. T Horiuchi C Kiyohara H Tsukamoto T Sawabe I Furugo S Yoshizawa A Ueda Y Tada T Nakamura Y Kimoto H Mitoma S Harashima S Yoshizawa T Shimoda S Okamura K Nagasawa M Harada, Ann Rheum Dis 2007 66 320 324 10.1136/ard.2006. 058917 17028114
17. Combination of TNF-RII, CYP1A1 and GSTM1 polymorphisms and the risk of Japanese SLE: findings from the KYSS study. T Horiuchi M Washio C Kiyohara H Tsukamoto Y Tada T Asami S Ide G Kobashi H Takahashi Kyushu Sapporo SLE Study Group, Rheumatology (Oxford) 2009 48 1045 1049 10.1093/rheumatology/kep166 19561157
18. Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. A Barton S John WE Ollier A Silman J Worthington, Arthritis Rheum 2001 44 61 65 10.1002/1529-0131(200101)44:1<61::AID-ANR9>3.0.CO;2-Q 11212177
19. Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes. JR Glossop PT Dawes AB Hassell DL Mattey, J Rheumatol 2005 32 1673 1678 16142859
20. Inflammation and necrosis promote tumour growth. J Vakkila MT Lotze, Nature Rev Immunol 2004 4 641 648 10.1038/nri1415
21. The hallmarks of cancer. D Hanahan RA Weinberg, Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931
22. TRAIL-induced apoptosis: between tumor therapy and immunopathology. N Corazza D Kassahn S Jakob A Badmann T Brunner, Ann N Y Acad Sci 2009 1171 50 58 10.1111/j.1749-6632.2009.04905.x 19723037
23. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. C Canova M Hashibe L Simonato M Nelis A Metspalu P Lagiou D Trichopoulos W Ahrens I Pigeot F Merletti L Richiardi R Talamini L Barzan GJ Macfarlane TV Macfarlane I Holctov V Bencko S Benhamou C Bouchardy K Kjaerheim R Lowry A Agudo X Castellsagué DI Conway PA McKinney A Znaor BE McCartan CM Healy M Marron P Brennan, Cancer Res 2009 69 2956 2965 10.1158/0008-5472.CAN-08-2604 19339270
24. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. E Vairaktaris C Yapijakis Z Serefoglou D Avgoustidis E Critselis S Spyridonidou A Vylliotis S Derka S Vassiliou E Nkenke E Patsouris, J Cancer Res Clin Oncol 2008 134 821 832 10.1007/s00432-008-0360-z 18273643
25. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. M Colakogullari E Ulukaya A Yilmaztepe Oral F Aymak B Basturk A Ursavas HB Oral, Cell Biochem Funct 2008 26 283 290 10.1002/cbf.1419 17654453
26. Association of polymorphisms in Tumor Necrosis Factor Alpha and Beta genes with increased risk for oral cancer. C Yapijakis Z Serefoglou A Vylliotis E Nkenke S Derka S Vassiliou D Avgoustidis FW Neukam E Patsouris E Vairaktaris, Anticancer Res 2009 29 2379 2386 19528505
27. CRP genetic polymorphism is associated with lymph node metastasis in thoracic esophageal squamous cell cancer. S Motoyama M Miura Y Hinai K Maruyama S Usami H Saito Y Minamiya S Satoh K Murata T Suzuki J Ogawa, Ann Surg Oncol 2009 16 2479 2485 10.1245/s10434-009-0525-2 19495883
28. Association of TNF-alpha and TNFR1 promoters and 3' UTR region of TNFR2 gene polymorphisms with genetic susceptibility to tobacco-related oral carcinoma in Asian Indians. R Gupta SC Sharma SN Das, Oral Oncol 2008 44 455 463 10.1016/j.oraloncology.2007.06.003 18206417
29. Toxicity grading criteria of the Japan Clinical Oncology Group (The Clinical Trial Review Committee of the Japan Clinical Oncology Group). K Tobinai A Kohno Y Shimada T Watanabe T Tamura K Takeyama M Narabayashi T Fukutomi H Kondo M Shimoyama K Suemasu Members of the Clinical Trial Review Committee of the Japan Clinical Oncology Group, Jpn J Clin Oncol 1993 23 250 257 8411739
30. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. R Matsuyama S Togo D Shimizu N Momiyama T Ishikawa Y Ichikawa I Endo C Kunisaki H Suzuki Y Hayasizaki H Shimada, Int J Cancer 2006 119 406 13 10.1002/ijc.21843 16477629